...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
【24h】

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

机译:收缩注意:受体酪氨酸激酶抑制剂Sunitinib和整联素拮抗剂肽HM-3显示出类似的脂质筏依赖性双相调控肿瘤血管生成和转移

获取原文

摘要

The authors have retracted this article [1] because the bands shown in Fig.?5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64?nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of this study. All authors agree to this retraction.
机译:作者已经缩回了本文[1],因为图5例中所示的带为GTP-RhOA /对照,GTP-RhoA / Sunitinib(2和64·NM)和GTP-RhoA / HM-3(4.5和72 um)不是作为本研究的一部分生成的数据。所有作者都同意此撤回。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号